DK2411397T3 - Isothiazol-pyrimidindionderivater som modulatorer af TRPA1 - Google Patents

Isothiazol-pyrimidindionderivater som modulatorer af TRPA1

Info

Publication number
DK2411397T3
DK2411397T3 DK10716049.1T DK10716049T DK2411397T3 DK 2411397 T3 DK2411397 T3 DK 2411397T3 DK 10716049 T DK10716049 T DK 10716049T DK 2411397 T3 DK2411397 T3 DK 2411397T3
Authority
DK
Denmark
Prior art keywords
trpa1
isothiazole
modulators
pyrimidinedione derivatives
pyrimidinedione
Prior art date
Application number
DK10716049.1T
Other languages
Danish (da)
English (en)
Inventor
Sukeerthi Kumar
Abraham Thomas
Sanjay Margal
Neelima Khairatkar-Joshi
Indranil Mukhopadhyay
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Application granted granted Critical
Publication of DK2411397T3 publication Critical patent/DK2411397T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK10716049.1T 2009-03-23 2010-03-22 Isothiazol-pyrimidindionderivater som modulatorer af TRPA1 DK2411397T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
PCT/IB2010/000834 WO2010109328A1 (en) 2009-03-23 2010-03-22 Isothiazolo-pyrimidinedione derivatives as trpa1 modulators

Publications (1)

Publication Number Publication Date
DK2411397T3 true DK2411397T3 (da) 2013-08-05

Family

ID=42236291

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10716049.1T DK2411397T3 (da) 2009-03-23 2010-03-22 Isothiazol-pyrimidindionderivater som modulatorer af TRPA1

Country Status (22)

Country Link
US (1) US8575178B2 (enExample)
EP (1) EP2411397B1 (enExample)
JP (1) JP2012521405A (enExample)
KR (1) KR20120001746A (enExample)
CN (1) CN102395592A (enExample)
AP (1) AP2011005888A0 (enExample)
AU (1) AU2010227224A1 (enExample)
BR (1) BRPI1009372A2 (enExample)
CA (1) CA2756534A1 (enExample)
DK (1) DK2411397T3 (enExample)
EA (1) EA201190191A1 (enExample)
ES (1) ES2424340T3 (enExample)
IL (1) IL215179A0 (enExample)
MX (1) MX2011009821A (enExample)
PE (1) PE20120764A1 (enExample)
PL (1) PL2411397T3 (enExample)
PT (1) PT2411397E (enExample)
SG (2) SG174403A1 (enExample)
SI (1) SI2411397T1 (enExample)
UA (1) UA107342C2 (enExample)
WO (1) WO2010109328A1 (enExample)
ZA (1) ZA201107646B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010227225A1 (en) 2009-03-23 2011-09-15 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as TRPA1 modulators
SG174402A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as trpa1 modulators
US8592398B2 (en) 2010-12-20 2013-11-26 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as TRPA1 antagonists
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
RU2014100744A (ru) 2011-06-13 2015-07-20 Гленмарк Фармасьютикалс С.А. Лечение респираторных нарушений с помощью trpa1 антагонистов
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
JP2014517062A (ja) 2011-06-22 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
TWI640519B (zh) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Ｈｅｃ１活性調控因子及其調節方法
JP2015500278A (ja) 2011-12-05 2015-01-05 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストと抗コリン剤とを含む医薬組成物
MX354014B (es) 2012-06-08 2018-02-08 Glenmark Pharmaceuticals Sa Amidas de compuestos de 2-amino-4-ariltiazol y sus sales.
SI2903965T1 (sl) 2012-10-01 2017-07-31 Orion Corporation Derivati n-prop-2-inil karboksamida in njihova uporaba kot antagonisti trpa1
CA2884767A1 (en) 2012-11-14 2014-05-22 Stephan Bachmann Imidazopyridine derivatives
HK1221161A1 (zh) 2013-06-20 2017-05-26 Glenmark Pharmaceuticals S.A. 包含trpa1拮抗剂的纳米颗粒制剂
CA2926389A1 (en) 2013-10-15 2015-04-23 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2015155306A1 (en) * 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
US20190175599A1 (en) 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
WO2018233648A1 (zh) * 2017-06-21 2018-12-27 南京明德新药研发股份有限公司 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物
CN112794860B (zh) * 2021-03-24 2021-06-29 上海肇钰医药科技有限公司 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) * 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2005077959A1 (en) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
US20090062258A1 (en) 2005-02-03 2009-03-05 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
JP5858557B2 (ja) * 2005-12-22 2016-02-10 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 疼痛を処置するためのｔｒｐａ１阻害剤
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
WO2009002933A1 (en) * 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Methods and compositions for treating disorders
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders

Also Published As

Publication number Publication date
SG174403A1 (en) 2011-10-28
PL2411397T3 (pl) 2013-10-31
EA201190191A1 (ru) 2012-11-30
JP2012521405A (ja) 2012-09-13
KR20120001746A (ko) 2012-01-04
EP2411397B1 (en) 2013-05-29
PT2411397E (pt) 2013-06-06
US20120010223A1 (en) 2012-01-12
HK1166081A1 (en) 2012-10-19
EP2411397A1 (en) 2012-02-01
ZA201107646B (en) 2012-06-25
SI2411397T1 (sl) 2013-07-31
PE20120764A1 (es) 2012-06-27
AU2010227224A1 (en) 2011-09-29
AU2010227224A2 (en) 2011-10-27
US8575178B2 (en) 2013-11-05
CA2756534A1 (en) 2010-09-30
CN102395592A (zh) 2012-03-28
ES2424340T3 (es) 2013-10-01
SG184766A1 (en) 2012-10-30
MX2011009821A (es) 2012-01-25
AP2011005888A0 (en) 2011-10-31
IL215179A0 (en) 2011-12-29
UA107342C2 (en) 2014-12-25
BRPI1009372A2 (pt) 2016-05-31
WO2010109328A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
DK2411397T3 (da) Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
DK2411396T3 (da) Thienopyrimidindionderivater som modulatorer af TRPA1
DK2411393T3 (da) Kondenserede pyrimidin-dionderivater som TRPA1-modulatorer
DK3124483T3 (da) Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer
DK2300465T3 (da) Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
DK3235812T3 (da) Deutererede derivater af ivacaftor
DK2475657T3 (da) 5-Alkynylthien-2-ylcarboxylsyrer som inhibitorer af flaviviridae-vira
DK3354657T3 (da) Fremgangsmåde til fremstilling af planteafledte proteiner
DK2310437T3 (da) Fremgangsmåde til kontinuerlig fremstilling af polyestere
DK2567524T3 (da) Reduktion af protokolspild
EP2563129A4 (en) N3-SUBSTITUTED N1-SULFONYL-5-FLUORPYRIMIDINONE DERIVATIVES
DK2421537T3 (da) Pyrazolylaminopyridiner som inhibitorer af FAK
DK2603232T3 (da) Stabile formuleringer af linaclotid
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
DK2526425T3 (da) Fremgangsmåde til diagnosticering af endometriel receptivitet
ECSP12011999A (es) Derivados benzamida sustituidos
DK2408446T3 (da) Anvendelse af farmaceutiske sammensætninger, der indeholder mesembrenon
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BR112012005371A2 (pt) desmontagem de componentes interligados
DK2405972T3 (da) Anvendelse af rosuvastatin lactoler som medikamenter
DK2260873T3 (da) Pcylering af proteiner
DK3070091T3 (da) Benzodioxolderivater som phosphodiesterasehæmmere
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
DK2800572T3 (da) Sammensætning af ellagitannin-rige ekstrakter
BRPI1011416A2 (pt) derivados de antraquinova novos